Payment overview · 2025
General Payments
$186.20
8 reported records · 6 companies
Healthcare provider profile · identity verified
Esther U Browne-King, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KENNETH CITY, FL · NPI 1780792853
Verified facts
What the public records show
CMS Open Payments records show Esther U Browne-King, M.D. received $186.20 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.44 | 25.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.78 | 24.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.39 | 16.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.21 | 16.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.07 | 9.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.31 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.20 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.78 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 344 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 69 |
| Gabapentin | Gabapentin | 251 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 80 |
| Losartan Potassium | Losartan Potassium | 205 | 58 |
| Montelukast Sodium | Montelukast Sodium | 153 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 122 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 122 | 43 |
| Jardiance | Empagliflozin | 120 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 44 |
| Famotidine | Famotidine | 109 | 39 |
| Methylprednisolone | Methylprednisolone | 109 | 96 |
| Donepezil Hcl | Donepezil Hcl | 108 | 20 |
| Eliquis | Apixaban | 105 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 21 |
| Celecoxib | Celecoxib | 99 | 30 |
| Trazodone Hcl | Trazodone Hcl | 99 | 29 |
| Alendronate Sodium | Alendronate Sodium | 98 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 24 |
| Metformin Hcl | Metformin Hcl | 93 | 27 |
| Potassium Chloride | Potassium Chloride | 91 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 87 | 40 |
| Azithromycin | Azithromycin | 78 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 73 | 19 |
| Omeprazole | Omeprazole | 69 | 25 |
| Allopurinol | Allopurinol | 65 | 19 |
| Calcitriol | Calcitriol | 65 | 14 |
| Glipizide Er | Glipizide | 64 | 18 |
| Furosemide | Furosemide | 63 | 18 |
| Ozempic | Semaglutide | 63 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | 29 |
| Valsartan | Valsartan | 60 | 14 |
| Nifedipine Er | Nifedipine | 59 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 16 |
| Carvedilol | Carvedilol | 57 | 19 |
| Meloxicam | Meloxicam | 57 | 14 |
| Finasteride | Finasteride | 56 | suppressed |
| Lisinopril | Lisinopril | 56 | 17 |
| Baclofen | Baclofen | 54 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Felodipine Er | Felodipine | 53 | 13 |
| Clonidine Hcl | Clonidine Hcl | 52 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Memantine Hcl | Memantine Hcl | 50 | 11 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 45 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Temazepam | Temazepam | 43 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 22 |
| Levofloxacin | Levofloxacin | 35 | 27 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 18 |
| Atenolol | Atenolol | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 13 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Dexamethasone | Dexamethasone | 19 | 19 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Benzonatate | Benzonatate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.20 · 8 records | GlaxoSmithKline, LLC. | ABRYSVO, CAPLYTA, COMIRNATY, JARDIANCE, PREVNAR 20, REPATHA, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error